ClinicalTrials.gg
CompletedNCT06308523Updated Oct 22, 2024

A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants

A Phase 1 interventional study of AP303 150 μg and Placebo 150 μg in Healthy Subjects, sponsored by Alebund Pharmaceuticals. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-22.

Sponsored by Alebund Pharmaceuticals · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The study will be a single center, double-blind, randomized, placebo-controlled, multiple-ascending-dose study to evaluate the safety, tolerability, PK and PD of AP303 following 2-week oral administration to healthy Chinese participants.

Read the detailed description

Eligible study participants will be enrolled and randomized into one of the two dose cohorts, each cohort will include 9 participants randomized to AP303 and placebo at 2:1 ratio (6 on AP303 and 3 on placebo).

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Alebund Pharmaceuticals is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Important Inclusion Criteria:

  1. Healthy male and female participants, 18-50 years of age.
  2. (body mass index) 18-27 kg/m2.

Important Exclusion criteria:

  1. History or symptoms of any kidney, liver, broncho-pulmonary, gastrointestinal, neurological, psychiatric, cardiovascular, endocrine/metabolic, hematological disease or cancer.
  2. Personal history of congenital long syndrome or family history of sudden death.
  3. People with a history of specific severe allergies, or severe allergic conditions or known allergies to the study or any of its ingredients or as judged by the investigator, or any acute confirmed significant allergic reactions to any drug, or multiple drug severe allergies (non-active hay fever is acceptable). Allowing for childhood asthma, history of mild eczema that has had no flare ups for ≥5 years or is fully resolved.
  4. History of having received or currently receiving any systemic anti-neoplastic or immunomodulatory treatment (including systemic oral or inhaled ) ≤6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study.
  5. Participants who have had significant acute infection, e.g., COVID-19, influenza, local infection, acute gastrointestinal symptoms or any other clinically significant illness within two weeks before study drug administration.
  6. Confirmed systolic BP greater than 140 or less than 90 mmHg, and diastolic BP greater than 90 or less than 50 mmHg at screening.
  7. Abnormalities of parameters and abnormal shape of ECG wave on screening ECG.
  8. Implantation of cardiac pacemaker or clinically significant arrhythmias.
  9. Estimated (eGFR) \<90 mL/min/1.73 m2 (using the CKD-EPI equation).
  10. Positive test at screening of any of the following: (HBsAg), (HCVAb), (HIV Ab) or syphilis AB.
  11. or AST >1.5 × , or any other clinically significant abnormalities in laboratory test results at screening.
  12. Dosed with a small-molecule or biologic drug within 30 days or 90 days, respectively, or 5 half-lives whichever is the longer) prior to first dose of this study.
  13. Donation of component (plasma or ) or whole blood ≥200 mL within 4 weeks prior to screening.
  14. Receipt of a within 4 weeks of prior to screening (Influenza and COVID-19 vaccines are allowed).
  15. Positive urine test for drugs of abus.
  16. History of drug and/or alcohol abuse or addiction.
  17. History (within 3 months of screening) of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol). Alcohol consumption within 48 hours before screening.
  18. Use of >5 cigarettes or equivalent nicotine-containing product per day.
  19. Taking any prescribed or over-the-counter medications (including vitamins or herbal remedies) within 30 days or 5 half-lives (whichever is the longer) of the first dose of study drug. Occasional paracetamol is allowed (see section on Permitted Therapy). Exceptions may be made on a case-by-case basis following discussion and agreement between the investigator and the sponsor.
  20. Medical or social conditions that would potentially interfere with the participant's ability to comply with the study visit schedule or the study assessments.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    AP303

    Drug: AP303 150 μg · Drug: AP303 300 μg

  • Placebo comparator
    Placebo

    Drug: Placebo 150 μg · Drug: Placebo 300 μg

Interventions

  • DrugAP303Studies of AP303AP303 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    AP303 Tablet 150 μg QD

  • DrugPlacebo 150 μg

    Placebo Tablet 150 μg QD

  • DrugAP303Studies of AP303AP303 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    AP303 Tablet 300 μg QD

  • DrugPlacebo 300 μg

    Placebo Tablet 300 μg QD

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum observed plasma concentration

    Time frame: Day 1, Day 3-14

  2. Tmax

    Time to maximum observed plasma concentration

    Time frame: Day 1, Day 3-14

  3. AUC0-24h

    Area under the plasma concentration versus time curve up to 24 hours

    Time frame: Day 1

  4. AUC0-last

    Area under the plasma concentration versus time curve up to the last measurable concentration

    Time frame: Day 1

  5. AUC0-inf

    Area under the plasma concentration versus time curve extrapolated to infinity

    Time frame: Day 1

  6. AUC0-t

    Area under the plasma concentration-time curve for a dosing interval

    Time frame: Day 3-14

  7. t1/2

    Apparent terminal half-life, computed as ln(2)/λz

    Time frame: Day 1, Day 3-14

  8. CL/F

    Apparent oral clearance calculated from Dose/ AUC0-inf

    Time frame: Day 1

  9. V/F

    Apparent volume of distribution of oral drug

    Time frame: Day 1, Day 3-14

  10. Cav

    average plasma concentration

    Time frame: Day 3-14

  11. Ctrough

    Trough plasma concentration

    Time frame: Day 3-14

  12. Rac

    Ratio of accumulation

    Time frame: Day 3-14

  13. Incidence and severity of adverse events

    Incidence and severity of adverse events

    Time frame: Day 1-28

  14. Incidence of laboratory abnormalities, based on hematology, clinical chemistry, coagulation and urinalysis test results

    Incidence of laboratory abnormalities, based on hematology, clinical chemistry, coagulation and urinalysis test results

    Time frame: Day 1-28

  15. Effect of AP303 on ECG parameters

    Heart rate in beats/min

    Time frame: Day 1-28

  16. Effect of AP303 on ECG parameters

    QT in ms

    Time frame: Day 1-28

  17. Effect of AP303 on ECG parameters

    PR in ms

    Time frame: Day 1-28

  18. Effect of AP303 on ECG parameters

    QRS in ms

    Time frame: Day 1-28

  19. Effect of AP303 on ECG parameters

    QTcF in ms

    Time frame: Day 1-28

  20. Effect of AP303 on ECG parameters

    QTcB in ms

    Time frame: Day 1-28

  21. Vital signs

    Effect of AP303 on vital signs, e.g. blood pressure

    Time frame: Day 1-28

  22. Effect of AP303 on physical examination result

    nature, frequency, and severity of abnormality of physical examination result

    Time frame: Day 1-28

  23. body weight

    Effect of AP303 on body weight, e.g. change of body weight after administration of AP303

    Time frame: Day 1-28

Secondary outcomes

  1. Fasting glucose

    Fasting glucose

    Time frame: Baseline, Days 5, 10, 14 and 28

  2. Fasting lipid profile

    Triglyceride, HDL-C, LDL-C, Total cholesterol

    Time frame: Baseline, Days 5, 10, 14 and 28

  3. Serum creatinine

    Serum creatinine

    Time frame: Baseline, Days 5, 10, 14 and 28

  4. eGFR

    Estimated glomerular filtration rate

    Time frame: Baseline, Days 5, 10, 14 and 28

07

Study locations

1 site
  • Peking University Third Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in May 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2024
First posted
Mar 13, 2024
StartActual
Mar 18, 2024
Primary completionActual
May 13, 2024
CompletionActual
May 13, 2024
Last update
Oct 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06308523
Lead sponsor
Alebund Pharmaceuticals
Responsible party
Sponsor
First posted
Mar 13, 2024
Start date
Mar 18, 2024
Primary completion
May 13, 2024
Completion
May 13, 2024
Last update
Oct 22, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AP303

Start the discussion